Kobayashi Pharmaceutical Co., Ltd.
KBYPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $165,600,000 | $173,455,000 | $166,258,000 | $155,252,000 |
| % Growth | -4.5% | 4.3% | 7.1% | – |
| Cost of Goods Sold | $77,997,000 | $77,079,000 | $73,927,000 | $66,478,000 |
| Gross Profit | $87,603,000 | $96,376,000 | $92,331,000 | $88,774,000 |
| % Margin | 52.9% | 55.6% | 55.5% | 57.2% |
| R&D Expenses | $9,109,000 | $9,004,000 | $8,327,000 | $7,522,000 |
| G&A Expenses | $5,160,000 | $29,869,000 | $5,024,000 | $5,200,000 |
| SG&A Expenses | $22,029,000 | $57,611,000 | $31,608,000 | $31,790,000 |
| Sales & Mktg Exp. | $16,869,000 | $27,742,000 | $26,584,000 | $26,590,000 |
| Other Operating Expenses | $31,605,000 | $3,981,000 | $25,722,000 | $23,390,000 |
| Operating Expenses | $62,743,000 | $70,596,000 | $65,657,000 | $62,702,000 |
| Operating Income | $24,860,000 | $25,780,000 | $26,669,000 | $26,065,000 |
| % Margin | 15% | 14.9% | 16% | 16.8% |
| Other Income/Exp. Net | -$10,946,000 | $1,779,000 | $1,280,000 | $1,570,000 |
| Pre-Tax Income | $13,914,000 | $27,559,000 | $27,950,000 | $27,636,000 |
| Tax Expense | $3,842,000 | $7,221,000 | $7,927,000 | $7,920,000 |
| Net Income | $10,067,000 | $20,338,000 | $20,022,000 | $19,715,000 |
| % Margin | 6.1% | 11.7% | 12% | 12.7% |
| EPS | 135.42 | 268.16 | 259.63 | 252.36 |
| % Growth | -49.5% | 3.3% | 2.9% | – |
| EPS Diluted | 135.42 | 268.16 | 259.59 | 252.36 |
| Weighted Avg Shares Out | 74,338 | 75,842 | 77,122 | 78,125 |
| Weighted Avg Shares Out Dil | 74,338 | 75,842 | 77,129 | 78,125 |
| Supplemental Information | – | – | – | – |
| Interest Income | $207,000 | $214,000 | $85,000 | $131,000 |
| Interest Expense | $28,000 | $29,000 | $18,000 | $18,000 |
| Depreciation & Amortization | $8,022,000 | $6,057,000 | $5,358,000 | $4,835,000 |
| EBITDA | $21,964,000 | $33,645,000 | $31,864,000 | $30,786,000 |
| % Margin | 13.3% | 19.4% | 19.2% | 19.8% |